Clinical Trial Update: Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating camrelizumab in combination with apatinib as second-line therapy for recurrent or metastatic adrenocortical carcinoma; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: West China Hospital | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: RECRUITING